ClinicalTrials.gg
Active, not recruitingNCT06531824Updated Nov 12, 2026

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A Phase 3 interventional study of BI 690517 and Placebo matching BI 690517 in Kidney Disease, Chronic, sponsored by Boehringer Ingelheim. Active, not recruiting at 562 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Enrollment updated12 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,371
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim — none open to participants now, 4 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Boehringer Ingelheim.

Enrollment
Largest of 10
8,371 · median 242
Started
2024
with 2 others
Phase 3
3 of 13
none open now
Registered
10th of 13
by date

Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, this one has the largest enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 3, and was the 10th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim as a file.
02

Study summary

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation.

After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study.

The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 5 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.

03

Conditions studied

  • Kidney Disease, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Evidence of chronic kidney disease (CKD) at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires:

    1. Chronic Kidney Disease Epidemiology Collaboration () eGFR ≥20 \<45 mL/min/1.73m² (irrespective of diabetes status); or
    2. No self-reported diabetes: CKD-EPI eGFR ≥45 \<90 mL/min/1.73m² with urine albumin-to-creatinine ratio (uACR) ≥150 mg/g (or protein-to-creatinine ratio ≥225 mg/g); or
    3. Self-reported diabetes: CKD-EPI eGFR ≥45 \<90 mL/min/1.73m² with uACR ≥30 mg/g (or protein-to-creatinine ratio ≥45 mg/g).
  • Neither requires an Aldosterone Synthase inhibitor (ASi) or Mineralocorticoid Receptor Antagonist (MRA), nor that such treatment is definitely inappropriate.

Key Exclusion Criteria:

  • Blood potassium of >5.2 mmol/L at screening visit
  • Blood (ALT) or Aspartate Transaminase (AST) >3x (ULN) at Screening visit (only one is required, with ALT preferred)
  • Known liver cirrhosis
  • On dialysis, functioning kidney transplant, or scheduled living donor transplant
  • Treated with new therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days
  • Receiving more than one Renin-Angiotensin System (RAS) inhibitor (i.e. on dual therapy with two of an Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB) or direct renin inhibitor)
  • Currently treated with an Mineralocorticoid Receptor Antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone)
  • Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8,371 participants (actual)

Study arms

  • Other
    Part 1: Run-in period (all participants)

    * Participant will receive empagliflozin (called Type E) together with study tablets (called Type F) prior to later randomisation to the main study treatment (Type M). * This run-in period allows empagliflozin to be established and have its effects on kidney function before randomisation, and to make sure participant can tolerate empagliflozin long-term. Participants will not routinely know whether type F treatment is active or inactive so that participants can become familiar with taking main study tablet (Type M) after randomization.

    Drug: Empagliflozin

  • Experimental
    Part 2: Randomized treatment, follow-up period, treatment group

    Drug: BI 690517 · Drug: Empagliflozin

  • Placebo comparator
    Part 2: Follow-up period, placebo group

    Drug: Placebo matching BI 690517 · Drug: Empagliflozin

Interventions

  • BI 690517 (called Type M randomized treatment)

    Also known as: Vicadrostat

  • DrugPlacebo matching BI 690517

    Placebo matching BI 690517

  • Empagliflozin (called Type E)

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.

    Kidney disease progression is defined as kidney failure or a sustained decline of ≥40% in estimated Glomerular Filtration Rate (eGFR) from randomization

    Time frame: up to 4 years

Secondary outcomes

  1. Key secondary outcome: Time to first event of kidney failure, hospitalization for heart failure or cardiovascular death

    Time frame: up to 4 years

  2. Key secondary outcome: Time to first event of hospitalization for heart failure or cardiovascular death

    Time frame: up to 4 years

  3. Key secondary outcome: Occurrences of hospitalizations from any cause (first and any subsequent, combined) or death from any cause

    Time frame: up to 4 years

  4. Key secondary outcome: Time to death from any cause

    Time frame: up to 4 years

  5. Key secondary outcome: Annual rate of change in eGFR from 1 month until last scheduled visit (i.e. chronic eGFR slope)

    Time frame: up to 4 years

  6. Time to first event of kidney disease progression or cardiovascular death

    Time frame: up to 4 years

07

Study locations

562 sites

Showing the first 100 of 562 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's planned 28 months is close to that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 1, 2024
StartActual
Aug 30, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 7 sites removed
Show 12 added (3 Brazil, 3 Australia, 2 Germany, 2 Italy, 1 United States, 1 United Kingdom)
  • Hospital Universitário Walter Cantidio - UFC · Fortaleza, Brazil
  • Hospital das Clinicas da Universidade Federal de Pernambuco · Recife, Brazil
  • St.-Josefs-Hospital Cloppenburg · Cloppenburg, Germany
  • Concord Hospital · Concord, Australia
  • Nepean Hospital · Kingswood, Australia
  • AOVO Clinical Trials · Southport, Australia
  • Hospital das Clinicas da Faculdade de Medicina da USP · São Paulo, Brazil
  • Bioresearch Partner · Miami, United States
  • Azienda Socio Sanitaria Territoriale Lariana · San Fermo della Battaglia, Italy
  • Azienda Socio Sanitaria Ligure 2 · Savona, Italy
  • Eynsham Medical Centre · Witney, United Kingdom
  • Herz und Diabeteszentrum NRW Bad Oeynhausen Universitätsklinik der Ruhr-Universität Bochum · Bad Oeynhausen, Germany
Show 7 removed
  • Hospital Universitário Walter Cantídio - UFC · Fortaleza, Brazil
  • Hospital das Clínicas da Universidade Federal de Pernambuco · Recife, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da USP · São Paulo, Brazil
  • Ospedale Sant'Anna di San Fermo della Battaglia · San Fermo della Battaglia, Italy
  • Azienda Sociosanitaria Ligure 2 · Savona, Italy
  • Eynsham Medical Group · Witney, United Kingdom
  • Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen · Bad Oeynhausen, Germany
across 4 updates, Oct 1, 2026 – Nov 12, 2026
Enrollment
11000 (estimated)→8371 (actual)
Oct 14, 2026
Show all 4 updates
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • Herz und Diabeteszentrum NRW Bad Oeynhausen Universitätsklinik der Ruhr-Universität Bochum · Bad Oeynhausen, Germany
    Show 1 removed
    • Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen · Bad Oeynhausen, Germany
    + 1 other change: verification date
  2. Oct 28, 2026
    4 sites added, 3 sites removed
    Show 4 added (2 Italy, 1 United States, 1 United Kingdom)
    • Bioresearch Partner · Miami, United States
    • Azienda Socio Sanitaria Territoriale Lariana · San Fermo della Battaglia, Italy
    • Azienda Socio Sanitaria Ligure 2 · Savona, Italy
    • Eynsham Medical Centre · Witney, United Kingdom
    Show 3 removed
    • Ospedale Sant'Anna di San Fermo della Battaglia · San Fermo della Battaglia, Italy
    • Azienda Sociosanitaria Ligure 2 · Savona, Italy
    • Eynsham Medical Group · Witney, United Kingdom
  3. Oct 14, 2026
    4 sites added, 1 site removed
    Show 4 added (3 Australia, 1 Brazil)
    • Concord Hospital · Concord, Australia
    • Nepean Hospital · Kingswood, Australia
    • AOVO Clinical Trials · Southport, Australia
    • Hospital das Clinicas da Faculdade de Medicina da USP · São Paulo, Brazil
    Show 1 removed
    • Hospital das Clínicas da Faculdade de Medicina da USP · São Paulo, Brazil
    Enrollment 11000 (estimated)→8371 (actual)
    + 1 other change: verification date
  4. Oct 1, 2026
    3 sites added, 2 sites removed
    Show 3 added (2 Brazil, 1 Germany)
    • Hospital Universitário Walter Cantidio - UFC · Fortaleza, Brazil
    • Hospital das Clinicas da Universidade Federal de Pernambuco · Recife, Brazil
    • St.-Josefs-Hospital Cloppenburg · Cloppenburg, Germany
    Show 2 removed
    • Hospital Universitário Walter Cantídio - UFC · Fortaleza, Brazil
    • Hospital das Clínicas da Universidade Federal de Pernambuco · Recife, Brazil

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06531824
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Aug 30, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vicadrostat

Start the discussion